Brukinsa (zanubrutinib)

News alerts, weekly reports and conference planners

Company:

BeiGene, Medison

Drug class:

BTK inhibitor

Related drugs:

‹

›

No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab + zanubrutinib Sensitive: A1 - Approval obinutuzumab + zanubrutinib Sensitive : A1	obinutuzumab + zanubrutinib Sensitive: A1 - Approval obinutuzumab + zanubrutinib Sensitive : A1
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 wild-type	Chronic Lymphocytic Leukemia	TP53 wild-type	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + zanubrutinib Sensitive: A2 - Guideline rituximab + zanubrutinib Sensitive : A2	rituximab + zanubrutinib Sensitive: A2 - Guideline rituximab + zanubrutinib Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
Chr del(11q)	Small Lymphocytic Lymphoma	Chr del(11q)	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
MYD88 wild-type	Waldenstrom Macroglobulinemia	MYD88 wild-type	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
IGH mutation	Small Lymphocytic Lymphoma	IGH mutation	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
BRAF mutation	Chronic Lymphocytic Leukemia	BRAF mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
ATM mutation	Chronic Lymphocytic Leukemia	ATM mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	venetoclax + obinutuzumab + zanubrutinib Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab + zanubrutinib Sensitive : C2	venetoclax + obinutuzumab + zanubrutinib Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab + zanubrutinib Sensitive : C2
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2	zanubrutinib Sensitive: C2 – Inclusion Criteria zanubrutinib Sensitive : C2
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	rituximab + zanubrutinib Sensitive: C2 – Inclusion Criteria rituximab + zanubrutinib Sensitive : C2	rituximab + zanubrutinib Sensitive: C2 – Inclusion Criteria rituximab + zanubrutinib Sensitive : C2
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	rituximab + zanubrutinib Sensitive: C2 – Inclusion Criteria rituximab + zanubrutinib Sensitive : C2	rituximab + zanubrutinib Sensitive: C2 – Inclusion Criteria rituximab + zanubrutinib Sensitive : C2

Brukinsa (zanubrutinib)

Associations
(55)

Associations
(55)

Brukinsa (zanubrutinib)

Associations(55)

Associations(55)

Associations
(55)

Associations
(55)